skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Hi Group recently I have taken a hit on ZTS (poor quarter results + SYK (acquisition another company) I was up 15% + 20% respectively presently breaking even or slightly up > to date. Should I sell one or both or keep one or both and why ? thanks for your advise.
Read Answer Asked by Terence on November 13, 2019
Q: I am thinking of selling pbh. Do you have a US stock in the same sector that you would prefer? Or would you just hold on pbh. Thanks.
Read Answer Asked by William on November 13, 2019
Q: Hi 5i Team
Are there two or three US companies that are poised for huge growth in the near future? Thanks!
Read Answer Asked by Conrad L on November 13, 2019
Q: A JPM analyst made the comments below in an article I read. 5i has also noted this rotation to date. Do you agree with the below and could you list 6-8 stocks in both the US and Canada that would benefit most?
=============
The massive rotation into value stocks that rocked investors two months ago is going to extend into 2020, according to J.P. Morgan’s quant guru Marko Kolanovic.

The quant, whose reports have moved markets in the past, predicted rotation, going so far as to call it a “once in a decade” trade.

Value names staged a comeback in September after years of underperformance as investors bet on economically sensitive, cheap stocks on hopes for a U.S.-China trade deal. The strategist believes the rotation has more room to run on the back of the improving macro environment.
Read Answer Asked by Tim on November 12, 2019
Q: I recently watched American democratic leadership debates and was quite surprised how anti-capitalist several of the main candidates were. Do you have any concerns of investing in companies subject to socialistic policies (I am assuming the democrats will possibly win the next election)?
Read Answer Asked by BRYAN on November 12, 2019
Q: Hello. I'm currently sitting on a loss with ILMN and you've mentioned a few times in recent months that it will likely take some time to recover. I'm wondering if it might be a good idea to move the money into some other businesses that are likely to grow faster than the rate at which ILMN recovers.

Sector differences aside, would you recommend any of the following as good candidates for this?

AMZN
FB
PYPL
None of the above (i.e. You expect ILMN to recover faster than the growth in any of the above.)

Thank you!
Read Answer Asked by Laxmyharan on November 11, 2019
Q: Hi 5i team,

This is a further question on healthcare and their binary outcomes on drug trials and approvals. I did buy MDT by the way based on its growth prospects and little or no dependence on drug approvals. This question is on AMRN and more generally the FDA approval process. AMRN has an upcoming date with the FDA on November 14th. From a business site, I quote “The Adcom review of the sNDA for Vascepa on its cardioprotective benefit is scheduled for November 14, 2019 with PDUFA planned for December 28, 2019”. What does that mean and how does one go about handicapping the odds of FDA approval or not? If this is largely a coin flip, then I will pass. If it is a progression towards likely approval, I may take a small position. I also understand that AMRN will be subject to a trading halt on Thursday while the review process is underway.

Thanks again for your insight into AMRN and the FDA approval process.
Dave

P.S. I notice that NXTC is down over 50% in the pre-market, a stock you mentioned in the FP for its crazy run last week. I thought tech stocks were volatile. They trade like utilities compared to drug stocks!
Read Answer Asked by Dave on November 11, 2019
Q: I note in your reply to Mark today you say that COLD is expensive; the question from an investment standpoint is how expensive are they? It seems that earnings expectations are all over the place for fiscal '19 and '20. First Call seems to expect over $1 in '20, TR 0.67, while PE ratios presented are anything between almost 300 and 130, which doesn't compute, and on top of that should COLD be evaluated as a REIT AFFO or other criteria or as an ordinary industrial equity? I also note that COLD has failed to meet earnings expectations for the past four consecutive quarters.

Taking into account actual earnings and volume growth could you please fill in some of these gaps and provide a basis for reasoned evaluation of this company's share pricing. The price run down in recent days could provide an attractive entry into an enterprise which appears to have significant prospects because of industry needs as well as fragmentation. Thank you.
Read Answer Asked by Mike on November 11, 2019
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!